MindinSpondin 2 inhibits hepatic steatosis, insulin resistance, and obesity via interaction with peroxisome proliferator-activated receptor α in mice.pdf.pdf

Research Article
Mindin/Spondin 2 inhibits hepatic steatosis, insulin resistance,
and obesity via interaction with peroxisome
proliferator-activated receptor a in mice
Li-Hua Zhu1,2, , Aibing Wang3, , Pengcheng Luo4,5, , Xinan Wang1,2, Ding-Sheng Jiang1,2,
Wei Deng1,2, Xiaofei Zhang6, Tao Wang1,2, Yi Liu6, Lu Gao7, Shumin Zhang1,2, Xiaodong Zhang6,
⇑
Jie Zhang4,5,à, Hongliang Li1,2, ,à
1Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan 430060, China; 2Cardiovascular Research Institute,
Wuhan University, Wuhan 430060, China; 3College of Veterinary Medicine, Hunan Agricultural University, Changsha 410128, China;
4Department of Urology, Renmin Hospital of Wuhan University, 99, Ziyang Rd, Wuhan, Hubei Province 430060, China;
5Huangshi Central Hospital, Hubei Polytechnic University, Huangshi, Hubei Province 435000, China; 6College of Life Sciences,
Wuhan University, Wuhan 430072, China; 7Department of Cardiology, Institute of Cardiovascular Disease, Union Hospital,
Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China
Background & Aims: Obesity and its related pathologies, such as insulin resistance (IR), which contribute to cardiovascular
hepatic steatosis, are associated with chronic inflammation and disease. Our previous studies indicated that Spondin 2 has a
protective role in the context of car